Skip to main content
Explore URMC


URMC / News / UR Cancer Experts Share Latest Evidence in Blood Disorders

UR Cancer Experts Share Latest Evidence in Blood Disorders

Wednesday, December 01, 2004

James P. Wilmot Cancer Center faculty members were invited to speak at a national gathering of hematology specialists to share their knowledge of the latest in science and the treatment of lymphoma, leukemia and other cancer disorders.

Richard I. Fisher, M.D., director of the Wilmot Cancer Center at the University of Rochester, will deliver a speech at an education program on diffuse aggressive lymphoma at the American Society of Hematology 2004 meeting Dec. 4-7 in San Diego. He will review the treatment guidelines for advanced stage aggressive lymphomas and discuss whether newly published clinical trials should alter the standard care.

Craig T. Jordan, Ph.D., a stem cell researcher at the Wilmot Cancer Center, will speak at a separate education session, outlining the data that supports the existence of a “leukemia stem cell.” He will provide an overview of the way leukemic stem cells function, and their relevance in solid-tumor cancers.

Several other Wilmot Cancer Center faculty members will also deliver presentations on a variety of topics, from preventing severe treatment side effects such as fevers, infections and blood clots in the veins, to predicting through gene analysis, which patients might respond best to certain therapies.

Fisher is chairman of the lymphoma committee of the National Cancer Institute’s Southwest Oncology Group, which oversees clinical trials are more that 250 medical institutions. His interest in lymphoma dates back to 1972, when he first began working in hematology research at the National Institutes of Health.

Jordan’s research focuses on the small number of cancer cells that possess stem-cell properties and tend to drive the growth of cancer, particular in leukemia. In addition, Jordan recently published an investigation into a new approach in treatment of acute myelogenous leukemia using targeted therapy in combination with chemotherapy.

                                                            # # #

Media Contact

Leslie Orr

(585) 275-5774

article hit counter